Oncoinvent ASA (STU:7BG) E10: €-1,176.63 (As of Dec. 2025)


STU:7BG Oncoinvent ASA STU:7BG
36 GF Score
Price €4.32
GF Value €84.74
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA E10?

Oncoinvent ASA STU:7BG -22.86% 36 E10 is €-1,176.63 as of Dec. 2025. GuruFocus rates STU:7BG with a GF Score™ of 36/100 and a GF Value™ of €84.74. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncoinvent ASA's adjusted earnings per share data for the fiscal year that ended in Dec. 2025 was €-10.562. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1,176.63 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-27), Oncoinvent ASA's current stock price is € 4.32. Oncoinvent ASA's E10 for the fiscal year that ended in Dec. 2025 was €-1,176.63. Oncoinvent ASA's Shiller PE Ratio of today is .


Oncoinvent ASA  (STU:7BG) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncoinvent ASA E10 Related Terms


Oncoinvent ASA E10 Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA E10 Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1,559.70 -1,176.63

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1,559.70 0.00 -1,176.63

STU:7BG vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Oncoinvent ASA's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncoinvent ASA Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncoinvent ASA's Shiller PE Ratio falls into.


STU:7BG
36GF Score
Oncoinvent ASA STU:7BG
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncoinvent ASA's adjusted earnings per share data for the fiscal year that ended in Dec. 2025 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-10.562/139.1000*139.1000
=-10.562

Current CPI (Dec. 2025) = 139.1000.

Oncoinvent ASA Annual Data

per_share_eps CPI Adj_EPS
201612 -1,572.094 104.400 -2,094.619
201712 -2,216.467 106.100 -2,905.849
201812 -1,995.885 109.800 -2,528.485
201912 -1,892.696 111.300 -2,365.445
202012 -1,791.578 112.900 -2,207.338
202112 -1,919.109 118.900 -2,245.148
202212 -2,087.903 125.900 -2,306.809
202312 -72.415 131.900 -76.368
202412 -47.748 134.800 -49.271
202512 -10.562 139.100 -10.562

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1,176.63 mean?
Oncoinvent ASA (STU:7BG) has a E10 of €-1,176.63 as of Dec. 2025. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's E10 too high?
Oncoinvent ASA's current E10 is €-1,176.63. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's E10 compare to VRTX and REGN?
Oncoinvent ASA's E10 of €-1,176.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current E10 is €-1,176.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (STU:7BG) has a current E10 of €-1,176.63. The stock's GF Value™ is €84.74, compared to a current price of €4.32 — trading 94.9% below its estimated fair value. The current E10 is €-1,176.63. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Oncoinvent ASA (STU:7BG), the current E10 is €-1,176.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (STU:7BG) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of €4.32 is trading 94.9% below its estimated GF Value™ of €84.74.

Key valuation signals for STU:7BG:

  • E10: €-1,176.63
  • GF Value™: €84.74 vs. price of €4.32 (94.9% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the STU:7BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for STU:7BG

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.32
Price
€84.74
GF Value